Current Screening Methodologies in Drug Discovery for Selected Human Diseases
Open Access
- 14 August 2018
- journal article
- review article
- Published by MDPI AG in Marine Drugs
- Vol. 16 (8), 279
- https://doi.org/10.3390/md16080279
Abstract
The increase of many deadly diseases like infections by multidrug-resistant bacteria implies re-inventing the wheel on drug discovery. A better comprehension of the metabolisms and regulation of diseases, the increase in knowledge based on the study of disease-born microorganisms’ genomes, the development of more representative disease models and improvement of techniques, technologies, and computation applied to biology are advances that will foster drug discovery in upcoming years. In this paper, several aspects of current methodologies for drug discovery of antibacterial and antifungals, anti-tropical diseases, antibiofilm and antiquorum sensing, anticancer and neuroprotectors are considered. For drug discovery, two different complementary approaches can be applied: classical pharmacology, also known as phenotypic drug discovery, which is the historical basis of drug discovery, and reverse pharmacology, also designated target-based drug discovery. Screening methods based on phenotypic drug discovery have been used to discover new natural products mainly from terrestrial origin. Examples of the discovery of marine natural products are provided. A section on future trends provides a comprehensive overview on recent advances that will foster the pharmaceutical industry.Keywords
Funding Information
- FCT (UID/Multi/04423/2013)
This publication has 192 references indexed in Scilit:
- An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicityCell Death & Disease, 2012
- A Historical Overview of Natural Products in Drug DiscoveryMetabolites, 2012
- Natural Product Libraries to Accelerate the High-Throughput Discovery of Therapeutic LeadsJournal of Natural Products, 2011
- Neuroprotective strategies involving ROS in Alzheimer diseaseFree Radical Biology & Medicine, 2011
- The Diarylheptanoid (+)-aR,11S-Myricanol and Two Flavones from Bayberry (Myrica cerifera) Destabilize the Microtubule-Associated Protein TauJournal of Natural Products, 2010
- Chagas diseaseThe Lancet, 2010
- An in vitro screening cascade to identify neuroprotective antioxidants in ALSFree Radical Biology & Medicine, 2009
- Medical biofilmsBiotechnology & Bioengineering, 2008
- A Phenotypic Small-Molecule Screen Identifies an Orphan Ligand-Receptor Pair that Regulates Neural Stem Cell DifferentiationCell Chemical Biology, 2007
- Trypan Blue Exclusion Test of Cell ViabilityCurrent Protocols in Immunology, 1997